Rainbow Coral’s division, Rainbow Biosciences has declared that it has started due diligence analysis for a possible joint venture or acquisition of n3D Biosciences, the company being a developer of an advanced nanoparticle cell-growth technology.
Patrick Brown, Chief Executive Officer at Rainbow Coral, stated that the sophisticated nanoparticle cell-growth technology is capable of advancing cell research, paving the way for a major breakthrough to scientists actively participating in the areas of neurological disorders, stem cells, oncology and much more. The capability to reproduce cells very nearly as they exist in the human body will make cell scientists to better understand and study cell activities in a laboratory environment, enabling the evolution of more significant results, Brown said.
Besides playing a role in providing new opportunities for upcoming cell research, n3D Biosciences has also started commercializing its products. The company has already delivered certain products to clinical scientists. Brown stated that this differentiates n3D Biosciences from other biosciences projects.
Brown further commented that once the acquisition is successfully finished, the company’s role will be to help n3D Biosciences to widen its market reach and improve its sales. Rainbow BioSciences competes with Gilead Sciences, Affymax, Amgen and Celgene for the development of novel medical technologies and innovations.
Source: http://www.rainbowbiosciences.com